

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/619,362	07/14/2003	A. Dean Sherry	UTAD 0004	6828	
27964	7590 10/14/2004		EXAMINER		
HITT GAINES P.C. P.O. BOX 832570			NWAONICHA, CHUKWUMA O		
	ON, TX 75083		ART UNIT PAPER NUMBE		
			1621		
			DATE MAILED: 10/14/2004	1	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
_	_	10/619,362	SHERRY ET AL.	SHERRY ET AL.	
Office Action Summary		Examiner	Art Unit		
		Chukwuma O. Nwaonicha			
The MAILING DATE Period for Reply	of this communication a	ppears on the cover sheet w	vith the correspondence address		
THE MAILING DATE OF T - Extensions of time may be available after SIX (6) MONTHS from the material of the period for reply specified above. If NO period for reply is specified at Failure to reply within the set or extensions.	FHIS COMMUNICATION e under the provisions of 37 CFR 1 ailing date of this communication. ve is less than thirty (30) days, a re bove, the maximum statutory perio tended period for reply will, by statu- ter than three months after the mail	1.136(a). In no event, however, may a	reply be timely filed rty (30) days will be considered timely. NTHS from the mailing date of this communic BANDONED (35 U.S.C. 8 133)	ation.	
Status					
1) Responsive to comm	nunication(s) filed on	·			
2a) This action is FINAL		nis action is non-final.			
			ters, prosecution as to the merit	s is	
closed in accordance	e with the practice under	Ex parte Quayle, 1935 C.[D. 11, 453 O.G. 213.		
Disposition of Claims					
4)⊠ Claim(s) <u>1-20</u> is/are ∣	pending in the applicatio	on.			
4a) Of the above clair	m(s) <u>13-20</u> is/are withdra	awn from consideration.			
5) Claim(s) is/are	e allowed.				
6)⊠ Claim(s) <u>1-12</u> is/are i	-				
7) Claim(s) <u>1-12</u> is/are	•				
8) Claim(s) are s	ubject to restriction and/	or election requirement.			
Application Papers					
9) The specification is ol	bjected to by the Examir	ner.			
10)☐ The drawing(s) filed o	on is/are: a)□ ac	ccepted or b) objected to	by the Examiner.		
Applicant may not requ	est that any objection to the	e drawing(s) be held in abeya	nce. See 37 CFR 1.85(a).		
			(s) is objected to. See 37 CFR 1.12		
11)∐ The oath or declaration	on is objected to by the E	Examiner. Note the attache	d Office Action or form PTO-152	2.	
Priority under 35 U.S.C. § 119	9				
12) Acknowledgment is m	nade of a claim for foreig	an priority under 35 U.S.C. 8	S 119(a)-(d) or (f)		
a) ☐ All b) ☐ Some * o		,,, p. 10 11, and 01 00 0.0.0.	3 1 10(d) (d) or (i).		
	s of the priority documer	nts have been received.			
		nts have been received in A	Application No.		
3. Copies of the o	certified copies of the pri	ority documents have been	received in this National Stage		
application from	m the International Burea	au (PCT Rule 17.2(a)).			
		st of the certified copies not	received.		
* See the attached detai	iled Office action for a lis	,			
	lled Office action for a lis				
Attachment(s)		4) 🗔 Intensiew 9	Summary (PTO-413)		
* See the attached detai Attachment(s) 1) \overline{\text{Notice of References Cited (PTC)}} Notice of Draftsperson's Patent 3) \overline{\text{Information Disclosure Statement}}	O-892) Drawing Review (PTO-948)	Paper No(Summary (PTO-413) s)/Mail Date nformal Patent Application (PTO-152)		

Application/Control Number: 10/619,362

Art Unit: 1621

DETAILED ACTION

Claims 1-20 are pending in the application.

Election/Restrictions

Applicant's election without traverse of Group I (claims 1-12) in the reply filed on 7/29/04 is acknowledged.

Abstract

The abstract of the disclosure is objected to because of undue length. Correction is required. See MPEP § 608.01(b).

Applicant is reminded of the proper content of an Abstract of the Disclosure.

In chemical patent abstracts for compounds or compositions, the general nature of the compound or composition should be given as well as its use, e.g., "The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics." Exemplification of a species could be illustrative of members of the class. For processes, the type reaction, reagents and process conditions should be stated, generally illustrated by a single example unless variations are necessary.

Complete revision of the content of the abstract is required on a separate sheet.

Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words. It is important that the abstract not exceed 150 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

Art Unit: 1621

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-12 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims recite "a carboxylate (CO₂H)". However, a carboxylate is CO₂⁻ group while CO₂H is a carboxyl group. Clarification and/or correction is requested.

The word "comprising" renders the claims indefinite. It is not clear whether the claims are directed to a compound or a composition.

Allowable Subject Matter

Claims 1-12 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The tetraazacyclododecane ligand of general formula I according to claim 1:

wherein all variables are as defined in the claims were neither found to be obvious nor anticipated by the prior art of record.

Prior art does not teach or suggest the presently claim magnetic resonance contrast agent of general formula II.

II

that enhances magnetic resonance imaging (MRI) contrast with the desired τ_M value.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chukwuma O. Nwaonicha whose telephone number is 571-272-2908. The examiner can normally be reached on Monday thru Friday, 8:30am to 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann R. Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1621

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chukwuma O. Nwaonicha, Ph.D.

Patent Examiner Art Unit: 1621

> Johann R. Richter, Ph.D., Esq. Supervisory Patent Examiner, Technology Center 1600